88 Kodiak Sciences Inc. Consolidated Statements of Stockholders’ Equity (in thousands, except share and per share amounts) Common Stock Additional Paid-In Accumulated Other Comprehensive Accumulated Total Stockholders’ Shares Amount Capital Income (Loss) Deficit Equity Balances at December 31, 2020 51,112,302 $ 5 $ 1,151,920 $ 53 $ (291,227) $ 860,751 Issuance of common stock upon exercise of stock options 463,796 — 7,743 — — 7,743 Issuance of common stock upon vesting of restricted stock units 93,218 — — — — — Issuance of common stock pursuant to employee stock purchase plan 6,958 — 484 — — 484 Issuance of common stock upon exercise of common stock warrants 149,983 — — — — — Stock-based compensation expense — — 61,385 — — 61,385 Other comprehensive loss — — — (53) — (53) Net loss — — — — (266,990) (266,990) Balances at December 31, 2021 51,826,257 5 1,221,532 — (558,217) 663,320 Issuance of common stock upon exercise of stock options 126,999 — 1,770 — — 1,770 Issuance of common stock upon vesting of restricted stock units 103,032 — — — — — Issuance of common stock pursuant to employee stock purchase plan 27,863 — 174 — — 174 Issuance of common stock upon exercise of common stock warrants 249,699 — — — — — Stock-based compensation expense — — 106,033 — — 106,033 Other comprehensive loss — — — (1,307) — (1,307) Net loss — — — — (333,823) (333,823) Balances at December 31, 2022 52,333,850 5 1,329,509 (1,307) (892,040) 436,167 Issuance of common stock upon exercise of stock options 7,528 — 60 — — 60 Issuance of common stock upon vesting of restricted stock units 116,403 — — — — — Issuance of common stock pursuant to employee stock purchase plan 50,821 — 182 — — 182 Stock-based compensation expense — — 88,556 — — 88,556 Other comprehensive loss — — — 1,307 — 1,307 Net loss — — — — (260,491) (260,491) Balances at December 31, 2023 52,508,602 $ 5 $ 1,418,307 $ — $ (1,152,531) $ 265,781 The accompanying notes are an integral part of these consolidated financial statements.